Featured Editorial

1. Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next 11/6/2025

   NeoVac CEO Jan Egberts, MD, discusses the science, regulation, and innovation shaping next-gen LNPs—and why true progress in mRNA therapeutics may depend more on understanding than on AI.

2. Overcoming CMC Challenges In The Development Of Conjugated LNP Platforms For In Vivo CAR-T Therapy 11/4/2025

   Overcoming CMC hurdles is key to advancing conjugated LNP platforms for in vivo CAR-T therapy, enabling scalable, precise mRNA delivery to T cells while maintaining stability, potency, and regulatory compliance.

3. Makary Talks Faster Drug Reviews, 'Continuous Trials,' DTC Ads 11/3/2025

   Part one of a two-part series on FDA Commissioner Martin Makary, M.D.'s comments at the Gailen Forum in New York City on October 30, 2025.

4. Beyond the Hype: Industry Experts on the Reality of mRNA in Cancer Care 10/31/2025

   When I asked a panel of experts at RNA Leaders why mRNA was best positioned to shine in oncology, I was met with a few expected talking points and — better yet — a few I wasn’t expecting. 

5. Tackling Challenges In RNA Stability And Organ Targeting 10/28/2025

   RNA therapeutics are reshaping medicine, but instability and limited organ targeting still pose challenges. Discover how next-gen lipid nanoparticles and smart delivery systems are advancing RNA precision.

6. Developing Exosome-Based RNA Therapeutics For CNS Regeneration 10/24/2025

   Inside the effort to use exosomes as natural nanocarriers that deliver RNA therapeutics safely across the blood–brain barrier to heal damaged neural tissue.

7. The 9 Fastest-Growing Outsourcing Segments 10/21/2025

   Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

8. Bridging RNA Innovation: A CEO's Guide To European Expansion 10/15/2025

   For RNA biotechs, Europe isn't just the next market — it's the ultimate test of strategy. Here's what CEOs need to know.

9. From Misinformation To Medicine: Forging Bipartisan Support to Reverse Anti-mRNA Policy 10/9/2025

   In this article, I’ll share some of the progress AMM has made and the barriers the organization/our industry is still facing in our efforts to reverse the policy decisions that have been made against mRNA today. Throughout the panel, the speakers also shared their thoughts on the types of messaging we should be considering and/or have started to see making an impact. 

10. Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA Therapeutics 10/6/2025

    While LNPs have emerged as the most promising non-viral delivery vehicles for mRNA therapeutics thus far, the field is rapidly expanding. To broaden mRNA’s applicability across a wider range of indications, companies are exploring innovative non-viral, non-LNP delivery vehicles, including polymers, engineered virus-like particles, and more.